Skip to main content
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
November 6, 2024
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
Participation in Leading Investor Conferences
October 28, 2024
New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI
September 23, 2024
New Treatment Insights into Switching to UZEDY® from Perseris®
September 23, 2024
Reporting of the 2024 Annual General Meeting
September 13, 2024
Presentation at the H.C. Wainwright 26th Annual Global Investment Conference (New York, September 9 to 11)
September 5, 2024
Olanzapine LAI: No PDSS Observed After Completion of c.99% of the Targeted Injections for Submission
September 5, 2024
Progress in the Development of the Products Portfolio and the R&D Pipeline
September 3, 2024
Participation terms in the Combined General Meeting
August 26, 2024
